B. Riley Wealth Advisors Inc. purchased a new position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 90,298 shares of the specialty pharmaceutical company’s stock, valued at approximately $133,000. B. Riley Wealth Advisors Inc. owned approximately 0.62% of Cumberland Pharmaceuticals at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Millennium Management LLC purchased a new position in Cumberland Pharmaceuticals during the fourth quarter worth approximately $46,000. Acadian Asset Management LLC boosted its position in Cumberland Pharmaceuticals by 27.8% during the first quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after purchasing an additional 40,949 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Cumberland Pharmaceuticals by 6.3% in the first quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after acquiring an additional 38,100 shares in the last quarter. Hedge funds and other institutional investors own 16.70% of the company’s stock.
Cumberland Pharmaceuticals Stock Performance
NASDAQ CPIX opened at $2.09 on Wednesday. The company has a market cap of $30.03 million, a PE ratio of -16.08 and a beta of 0.24. The stock’s 50 day simple moving average is $1.87 and its 200-day simple moving average is $1.72. Cumberland Pharmaceuticals Inc. has a 1-year low of $1.43 and a 1-year high of $2.91. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.62 and a quick ratio of 1.21.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on Cumberland Pharmaceuticals in a research report on Monday. They issued a “hold” rating on the stock.
Check Out Our Latest Research Report on CPIX
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
See Also
- Five stocks we like better than Cumberland Pharmaceuticals
- Best Aerospace Stocks Investing
- Election Stocks: How Elections Affect the Stock Market
- How to Calculate Return on Investment (ROI)
- Looking Into Renewable Energy Trends? Your Best Bets
- How to Invest in the FAANG Stocks
- Over Sold and Left for Dead, High Yield Verizon Raises Guidance
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
